Department of Basic Biomedical Sciences, Sanford School of Medicine, University of South Dakota, Vermillion, SD 57069, USA.
Endocrinology. 2013 Jul;154(7):2542-52. doi: 10.1210/en.2012-2087. Epub 2013 Apr 17.
Thyroid hormones (THs) play a pivotal role in regulating cardiovascular homeostasis. To provide a better understanding of the coordinated processes that govern cardiac TH bioavailability, this study investigated the influence of serum and cardiac TH status on the expression of TH transporters and cytosolic binding proteins in the myocardium. In addition, we sought to determine whether the administration of T(3) (instead of T(4)) improves the relationship between THs in serum and cardiac tissue and cardiac function over a short-term treatment period. Adult female Sprague Dawley rats were made hypothyroid by 7 weeks treatment with the antithyroid drug 6-n-propyl-2-thiouracil (PTU). After establishing hypothyroidism, rats were assigned to 1 of 5 graded T(3) dosages plus PTU for a 2-week dose-response experiment. Untreated, age-matched rats served as euthyroid controls. PTU was associated with depressed serum and cardiac tissue T(3) and T(4) levels, arteriolar atrophy, altered TH transporter and cytosolic TH binding protein expression, fetal gene reexpression, and cardiac dysfunction. Short-term administration of T(3) led to a mismatch between serum and cardiac tissue TH levels. Normalization of serum T(3) levels was not associated with restoration of cardiac tissue T(3) levels or cardiac function. In fact, a 3-fold higher T(3) dosage was necessary to normalize cardiac tissue T(3) levels and cardiac function. Importantly, this study provides the first comprehensive data on the relationship between altered TH status (serum and cardiac tissue), cardiac function, and the coordinated in vivo changes in cardiac TH membrane transporters and cytosolic TH binding proteins in altered TH states.
甲状腺激素 (THs) 在调节心血管稳态中起着关键作用。为了更好地理解调节心脏 TH 生物利用度的协调过程,本研究调查了血清和心脏 TH 状态对心肌中 TH 转运体和胞质结合蛋白表达的影响。此外,我们还试图确定在短期治疗期间,给予 T(3)(而非 T(4))是否能改善血清和心脏组织中 TH 与心脏功能之间的关系。通过 7 周用抗甲状腺药物 6-正丙基-2-硫代尿嘧啶 (PTU) 处理成年雌性 Sprague Dawley 大鼠来制造甲状腺功能减退症。建立甲状腺功能减退症后,将大鼠分为 5 个 T(3) 剂量组加 PTU 进行为期 2 周的剂量反应实验。未处理的、年龄匹配的大鼠作为甲状腺功能正常对照。PTU 与血清和心脏组织 T(3) 和 T(4) 水平降低、小动脉萎缩、TH 转运体和胞质 TH 结合蛋白表达改变、胎儿基因重新表达和心脏功能障碍有关。短期给予 T(3) 导致血清和心脏组织 TH 水平不匹配。血清 T(3) 水平的正常化与心脏组织 T(3) 水平或心脏功能的恢复无关。事实上,需要 3 倍更高的 T(3) 剂量才能使心脏组织 T(3) 水平和心脏功能正常化。重要的是,本研究首次提供了关于改变的 TH 状态(血清和心脏组织)、心脏功能以及改变的 TH 状态下心脏 TH 膜转运体和胞质 TH 结合蛋白的体内协调变化之间关系的全面数据。